Contact details |
Revenue by geography |
Lochhamer Str. 11 82152 Planegg/Martinsried Germany +49 (0)89 2000 330 www.medigene.com |
N/A |
Contact details |
Lochhamer Str. 11 82152 Planegg/Martinsried Germany +49 (0)89 2000 330 www.medigene.com |
Revenue by geography |
N/A |
Management team |
|
CEO and CSO: Dolores Schendel |
CFO: Thomas Taapken |
Professor Dr Dolores Schendel joined Medigene as Chief Scientific Officer in 2014 with the acquisition of Trianta Immunotherapies (now Medigene Immunotherapies) where she was a majority founding member and has been Managing Director since 2013. She was appointed CEO with effect from April 2016. From 1998-2013, Professor Schendel was director of the Institute of Molecular Immunology of the German Research Center for Environmental Health at the Helmholtz Center in Munich. Previously she served as a university professor for Immunology at the Ludwig-Maximilian-University, focusing on human cellular immunology and T-cell responses within the field of oncology. Professor Schendel is the author of more than 200 scientific publications, has spent several decades as a scientific review board member in various research organisations such as the German Research Foundation, German Cancer Aid and the European Research Council. |
Dr Taapken spent more than five years at Epigenomics AG, initially as CFO and subsequently, from October 2012, as its CEO/CFO. He led the company’s efforts in gaining regulatory approval for the first blood-based molecular diagnostic cancer screening test by the FDA and oversaw its subsequent introduction into the US market. Prior to this he served as CFO at Biotie Therapies Corp (now Acorda Therapeutics) and its predecessor companies for six years, spent seven years as a venture capital investor at DVC Deutsche Venture Capital and San Francisco-based US venture capital firm Burrill & Company and worked for several years at Sanofi (originally Hoechst AG) in the US and Germany, managing corporate venture capital activities, as well as in the areas of corporate & business development and research. |
COO: Dave Lemus |
CMO: Dr Kai Pinkernell |
Dave Lemus has been vice chairman of the Supervisory Board of Medigene from 2013 until end 2015 when he joined the management board in January 2016 as COO. Prior to this, he served as CEO of Sigma Tau Pharmaceuticals, where he played a pivotal role in the turnaround of the company’s operations. During his time as CEO at Sigma Tau, Mr. Lemus presided over the FDA approval and subsequent successful commercial product launch of a rare disease therapeutic, in addition to the commercial revival of the company’s lead oncology product which resulted in its successful sale for US$900m to Baxalta (Shire) in July 2015. From 1998 to 2011, Mr Lemus was the CFO and executive vice president of MorphoSys, where he launched Germany’s first biotech IPO in 1999. |
Dr Kai Pinkernell has been responsible for the clinical advancement of Medigene's immunotherapy platforms since February 2016. Prior to joining Medigene, he held leading positions at Miltenyi Biotech GmbH, Bergisch Gladbach, Germany, most recently as global head of clinical business and head of clinical development. Previously, Dr Pinkernell was with Cytori Therapeutics, San Diego, US, as senior director of regenerative cell technology. He studied medicine and received his MD from the Westfaelische-Wilhems University in Muenster, Germany. |
Management team |
CEO and CSO: Dolores Schendel |
Professor Dr Dolores Schendel joined Medigene as Chief Scientific Officer in 2014 with the acquisition of Trianta Immunotherapies (now Medigene Immunotherapies) where she was a majority founding member and has been Managing Director since 2013. She was appointed CEO with effect from April 2016. From 1998-2013, Professor Schendel was director of the Institute of Molecular Immunology of the German Research Center for Environmental Health at the Helmholtz Center in Munich. Previously she served as a university professor for Immunology at the Ludwig-Maximilian-University, focusing on human cellular immunology and T-cell responses within the field of oncology. Professor Schendel is the author of more than 200 scientific publications, has spent several decades as a scientific review board member in various research organisations such as the German Research Foundation, German Cancer Aid and the European Research Council. |
CFO: Thomas Taapken |
Dr Taapken spent more than five years at Epigenomics AG, initially as CFO and subsequently, from October 2012, as its CEO/CFO. He led the company’s efforts in gaining regulatory approval for the first blood-based molecular diagnostic cancer screening test by the FDA and oversaw its subsequent introduction into the US market. Prior to this he served as CFO at Biotie Therapies Corp (now Acorda Therapeutics) and its predecessor companies for six years, spent seven years as a venture capital investor at DVC Deutsche Venture Capital and San Francisco-based US venture capital firm Burrill & Company and worked for several years at Sanofi (originally Hoechst AG) in the US and Germany, managing corporate venture capital activities, as well as in the areas of corporate & business development and research. |
COO: Dave Lemus |
Dave Lemus has been vice chairman of the Supervisory Board of Medigene from 2013 until end 2015 when he joined the management board in January 2016 as COO. Prior to this, he served as CEO of Sigma Tau Pharmaceuticals, where he played a pivotal role in the turnaround of the company’s operations. During his time as CEO at Sigma Tau, Mr. Lemus presided over the FDA approval and subsequent successful commercial product launch of a rare disease therapeutic, in addition to the commercial revival of the company’s lead oncology product which resulted in its successful sale for US$900m to Baxalta (Shire) in July 2015. From 1998 to 2011, Mr Lemus was the CFO and executive vice president of MorphoSys, where he launched Germany’s first biotech IPO in 1999. |
CMO: Dr Kai Pinkernell |
Dr Kai Pinkernell has been responsible for the clinical advancement of Medigene's immunotherapy platforms since February 2016. Prior to joining Medigene, he held leading positions at Miltenyi Biotech GmbH, Bergisch Gladbach, Germany, most recently as global head of clinical business and head of clinical development. Previously, Dr Pinkernell was with Cytori Therapeutics, San Diego, US, as senior director of regenerative cell technology. He studied medicine and received his MD from the Westfaelische-Wilhems University in Muenster, Germany. |
Principal shareholders |
(%) |
QVT |
15 |
Aviva |
7 |
DJS Montana |
4 |
Ridgeback |
3 |
|
Companies named in this report |
Amgen, Pfizer, Cellectis, Shire, Precision Biosciences, Celgene, June Therapeutics, Kite Pharma, bluebird bio, Ziopharm, Atara Biotherapeutics, Lion Biotechnologies, Bellicum Pharmaceuticals, Nantkwest, Celyad, Northwest Biotherapeutics, Argos Therapeutics, Immunocellular Therapeutics, Catherex, Immunocore, Syngentis |
|